StockData

Bolt Biotherapeutics vs Whitehawk Therapeutics

BOLT and WHWK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BOLT and WHWK compare

Whitehawk Therapeutics is the larger company, worth 15 times as much as Bolt Biotherapeutics ($172M against $11.2M).

Bolt Biotherapeutics grew revenue faster over the last twelve months (−51.3% versus −100% for Whitehawk Therapeutics).

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBOLTWHWK
Size and price
Market cap$11.2M$172M
Share price$5.80$3.01
Change, 1 year23.4%44.0%
Change, 5 years−96.8%−86.6%
Beta (5Y)0.102.36
Employees2323
StockData Score
Total score88
Valuation score11
Growth score1 (better)0
Performance score11
Health score56 (better)
Dividend score00
Valuation
P/S4.4×–
P/B1.3×0.9× (better)
FCF yield–−40.4%
Fair value$5.43–
Margin of safety−6.8%–
Growth
Revenue growth (TTM)−51.3% (better)−100%
Revenue growth, 5Y average102% (better)−12.6%
Profitability
Operating margin−1098%–
Net margin−1034%–
Return on equity−129%−45.0% (better)
Financial health
Debt / equity0.000.00
Current ratio2.0517.38 (better)
Altman Z-score−20.866.13 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield−0.27%–
Shareholder yield−0.27%0.00% (better)
Ownership
Held by institutions31.0%75.8%
Held by insiders12.2%49.9%
Insider net buying, 12 months$196K (better)−$2.6M
Short interest, % of float2.8%8.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.